Lasa Supergenerics narrows net loss to ₹416.44 lakh in Q4FY26

1 min read     Updated on 30 May 2026, 10:02 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Lasa Supergenerics narrowed its net loss to ₹416.44 lakh for Q4FY26 from ₹1,429.11 lakh in Q4FY25, with revenue from operations falling to (₹13.15) lakh due to a production halt caused by a fire incident. The statutory auditor, Gupta Rustagi & Co., issued a qualified opinion due to insufficient evidence on the fire's financial impact and the lack of impairment assessment for intangible assets worth ₹1,667.05 lakh. For the full year FY26, the company reported a net loss of ₹3,409.03 lakh on a total income of ₹2,534.05 lakh, while facing operational challenges like labour unrest.

powered bylight_fuzz_icon
41621233

*this image is generated using AI for illustrative purposes only.

Lasa Supergenerics reported a net loss of ₹416.44 lakh for the quarter ended March 31, 2026, a significant improvement from the net loss of ₹1,429.11 lakh in the corresponding quarter of the previous year. Revenue from operations for the quarter stood at (₹13.15) lakh, a steep decline from ₹3,913.77 lakh in Q4FY25, primarily due to a complete halt in production following a fire incident at its Ratnagiri factory. The company’s total income for the quarter was (₹9.08) lakh.

The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The statutory auditor, Gupta Rustagi & Co., issued a qualified opinion on the financial results. The qualification cites insufficient appropriate audit evidence regarding the completeness and accuracy of the financial impact of the fire incident that occurred on May 18, 2025. Additionally, the auditor qualified the opinion regarding the impairment of intangible assets, which include patents, goodwill, and software aggregating to ₹1,667.05 lakh, as the company has not carried out an impairment assessment.

Financial Performance

Particulars Quarter ended Mar 31, 2026 (₹ in Lakhs) Quarter ended Mar 31, 2025 (₹ in Lakhs)
Revenue from Operations (13.15) 3,913.77
Total Income (9.08) 4,152.94
Total Expenses 342.32 3,973.16
Net Profit / (Loss) (416.44) (1,429.11)
Earnings Per Share (Basic) (0.83) (2.85)

For the full year ended March 31, 2026, the company reported a net loss of ₹3,409.03 lakh on a total income of ₹2,534.05 lakh. The auditor emphasized the write-off of Capital Work-in-Progress amounting to ₹46.27 lakh during the year as an exceptional item. The company faces significant operational challenges, including labour unrest and obstruction by an unrecognized union preventing access to the factory for damage assessment. The management stated it is exploring alternative options such as contract manufacturing or leasing the facility to restore operations.

Historical Stock Returns for Lasa Supergenerics

1 Day5 Days1 Month6 Months1 Year5 Years
-0.84%+1.71%+2.72%-12.80%-47.96%-89.34%

What is the estimated timeline for resuming production at the Ratnagiri factory given the ongoing labor unrest?

How will the company fund operations and fixed costs during the extended halt in production?

What specific steps will management take to address the auditor's concerns regarding the impairment assessment of intangible assets?

Lasa Supergenerics Board Meeting Scheduled on May 29, 2026 to Approve Q4 FY26 Audited Financial Results

1 min read     Updated on 19 May 2026, 04:21 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Lasa Supergenerics has intimated stock exchanges of a board meeting scheduled for May 29, 2026, pursuant to Regulation 29 of the SEBI (LODR) Regulations, 2015. The meeting will consider and approve the audited financial results for the quarter and year ended March 31, 2026. The company's trading window will remain closed until 48 hours after the declaration of results, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The intimation, dated May 19, 2026, was signed by Director Ganesh Potdar (DIN: 11455401).

powered bylight_fuzz_icon
40733482

*this image is generated using AI for illustrative purposes only.

Lasa Supergenerics has notified the stock exchanges of an upcoming board meeting, scheduled for Friday, May 29, 2026, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, referenced as LASA/SE/26-27/05 and dated Tuesday, May 19, 2026, was submitted to both BSE Limited and the National Stock Exchange of India Limited.

Board Meeting Agenda

The board meeting has been convened to address the following key items:

  • Consideration, approval, and recording of the audited financial results of the company for the quarter and the year ended March 31, 2026
  • Discussion of any other matter with the permission of the Chairperson

The following table summarises the key details of the scheduled board meeting:

Parameter: Details
Meeting Date: Friday, May 29, 2026
Purpose: Approval of audited financial results
Period Under Review: Quarter and year ended March 31, 2026
Regulatory Reference: Regulation 29, SEBI (LODR) Regulations, 2015
Intimation Date: Tuesday, May 19, 2026
Reference Number: LASA/SE/26-27/05

Trading Window Closure

In line with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct, the trading window for Lasa Supergenerics shares will continue to remain closed until 48 hours after the declaration of the audited financial results for the quarter and the year ended March 31, 2026. This measure is standard practice to prevent insider trading ahead of material financial disclosures.

Regulatory Disclosures

The board meeting intimation has been made available on the company's official website at www.lasalabs.com , as well as on the websites of the stock exchanges at www.bseindia.com and www.nseindia.com . The intimation was signed by Ganesh Potdar, Director (DIN: 11455401), on behalf of Lasa Supergenerics.

Historical Stock Returns for Lasa Supergenerics

1 Day5 Days1 Month6 Months1 Year5 Years
-0.84%+1.71%+2.72%-12.80%-47.96%-89.34%

How might Lasa Supergenerics' FY2026 annual financial results compare to its previous year's performance in terms of revenue growth and profitability margins?

Will the audited financial results trigger any dividend announcement or capital allocation decisions by the Lasa Supergenerics board?

How could Lasa Supergenerics' FY2026 results influence investor sentiment and stock price movement once the trading window reopens?

More News on Lasa Supergenerics

1 Year Returns:-47.96%